We are a diverse team of viral immunologists, molecular virologists, and protein engineers. Together, we use our expertise to inform vaccine development and therapeutic antibody discovery for coronaviruses and other emerging and re-emerging viruses. We aim to understand the immune landscape of viral surface proteins, decipher the influence of immune responses on the clinical outcome following natural viral infection, and translate our findings to rationally design and evaluate novel vaccine concepts… all in the name of pandemic preparedness.
Protection from SARS-CoV-2 Delta one year after mRNA- 1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lun
A study looking at immunity against the SARS-CoV-2 Delta variant one year after mRNA vaccination
Stabilized coronavirus spike stem elicits a broadly protective antibody
Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subunit, which are poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy.